San Diego Biotech and Defense Tech: 9 Restructuring Rules When Your Collateral Is a Patent Portfolio

The Only Page in This Library Written for a Borrower With No Accounts Receivable

Every other restructuring page on this site rests on an assumption that fails completely in Sorrento Valley and Torrey Pines, which is that a business in trouble owns a stream of invoices somebody eventually pays. Look at four companies in that description. A Series A antibody company, a Class II device startup working through a 510(k), a contract research organization eighteen months from its first commercial study, and an unmanned systems subcontractor living on a Phase II award and one prime relationship. All four share a balance sheet where the accounts receivable line is either small, lumpy, or genuinely zero. What sits in its place is a patent family, a set of in-licenses, and a regulatory file nobody outside the company can read. Beside that sits a funding agreement with an investor who has promised the next tranche only if certain things happen by certain dates.

That changes the mechanics of a workout completely, because a creditor negotiating with a distributor is arguing about a discount on money that already exists, while a creditor negotiating with a pre-revenue company is arguing about a claim on property it would struggle to sell. The funder that filed a financing statement covering all general intangibles is perfected in your intellectual property, which surprises most founders, and it is also holding collateral with no recognized market, which surprises most funders when they finally try to realize on it. Both facts are true at once, and the gap between them is where a settlement gets negotiated.

The nine rules below run in the order a file actually gets worked, starting with what the lien touches and ending with what a change of ownership triggers on the defense side. Federal law does more of the work here than state law, which is unusual for this subject. The Patent Act, the Copyright Act, the Bayh-Dole framework, the federal grant rules, the export control regime and the foreign investment review statute all reach into a transaction that a broker priced in an afternoon off three months of bank statements. San Diego also sits in the Ninth Circuit, which matters more than usual here, because the two appellate decisions that settle where a security interest in patents and copyrights gets perfected are both Ninth Circuit law and both came out of California cases.

One concession before any of it, because it should shape how you read the rest. A funder holding a blanket lien on a company with no product revenue is not in a strong position, and a great many of these files settle at a real discount for exactly that reason. A company whose next tranche is conditional is not in a strong position either, and the party that runs out of time first usually pays for it. Speed matters more on these files than on almost any other type we work, because enterprise value at a pre-revenue company is an expectation rather than an asset, and expectations evaporate faster than collateral does.

1. Sort What the Lien Sits On Before Anyone Quotes a Number

Pull the financing statements first, and read the collateral descriptions rather than the creditor names, because the phrase that decides most of this file is usually one line on a printed form. Cal. Com. Code §9102(a)(42) defines a general intangible as any personal property, including things in action, other than accounts, chattel paper, commercial tort claims, deposit accounts, documents, goods, instruments, investment property, letter-of-credit rights, letters of credit, money, and unextracted minerals. The same paragraph adds that the term includes payment intangibles and software, and that residual category is where your issued patents, your pending applications, your trade secrets and know-how, your regulatory submissions, your assay data packages and every license you hold all live.

The filing itself is in Sacramento rather than San Diego. Cal. Com. Code §9501(a)(2) puts the financing statement in the office of the Secretary of State in every case except as-extracted collateral, timber, and fixture filings, so a county recorder search tells you nothing about who has a claim on your platform. Run the state index under the exact registered entity name, then under every prior name the company used. A filing made against a Delaware corporation before a name change or a reincorporation frequently sits on the index where nobody thinks to look, and it keeps its original priority date the whole time.

From the funder’s side of the table, the blanket description is not a considered judgment about your technology. Filing costs almost nothing, §9502(a) requires only three things for sufficiency, and §9502(d) even permits a filing before the security agreement is signed, so the rational move for any funder is to describe everything and sort it out later. That is why a company with $40,000 of accounts receivable and a twelve-patent estate ends up with four financing statements describing the same universe of collateral, and it is also why the priority date of each one matters far more than the language any of them uses.

What the exercise produces is a map, and the map is what a negotiation actually runs on. It starts with each filing dated and each secured party matched to the funding agreement it belongs to. You want each collateral description read for whether it reaches equipment and deposit accounts as well as intangibles, and every termination statement that was promised and never filed written down as an open item. Doing this before the first call is the difference between negotiating from a document and negotiating from memory, and funders can hear which one you are doing within about ninety seconds.

2. Patents Perfect in Sacramento and Registered Copyrights May Not

The single most expensive misconception in this area is that a security interest in intellectual property has to be recorded with a federal agency, and the Ninth Circuit answered that question for patents twenty-five years ago in a California bankruptcy appeal. In re Cybernetic Services, Inc., 252 F.3d 1039 (9th Cir. 2001), framed the question as whether 35 U.S.C. §261 or Article 9 as adopted in California “requires the holder of a security interest in a patent to record that interest with the federal Patent and Trademark Office (PTO) in order to perfect the interest as against a subsequent lien creditor.” The court answered that “neither the Patent Act nor Article 9 so requires,” and its conclusion is worth reading literally: “Because 35 U.S.C. §261 concerns only transactions that effect a transfer of an ownership interest in a patent, the Patent Act does not preempt Article 9.”

Copyright runs the other way, and the reason is a definition rather than a policy, because Title 17 defines a transfer of copyright ownership at 17 U.S.C. §101 as “an assignment, mortgage, exclusive license, or any other conveyance, alienation, or hypothecation of a copyright.” A security interest is therefore textually inside the federal recording scheme in a way it never was under §261, and §205(c) gives recordation the effect of constructive notice only where the document identifies the work and “registration has been made for the work.” Section 205(d) then resolves conflicting transfers in favor of the one recorded within one month of execution in the United States, or two months if executed abroad, or at any time before the later transfer is recorded.

The Ninth Circuit drew the line in In re World Auxiliary Power Co., 303 F.3d 1120 (9th Cir. 2002). It adopted the holding of In re Peregrine Entertainment, Ltd., 116 B.R. 194 (C.D. Cal. 1990), that “for registered copyrights, the only proper place to file is the Copyright Office.” As to unregistered copyrights it concluded that “the California U.C.C. has not stepped back in deference to federal law, and federal law has not preempted the U.C.C.” For a software or bioinformatics company that never registers anything, the state filing works, but for one that registered a code base or a device manual, a creditor who filed only in Sacramento has a defect worth finding.

Trademarks follow the patent pattern rather than the copyright pattern, because the Lanham Act at 15 U.S.C. §1060(a)(4) voids an unrecorded assignment against a subsequent purchaser without notice, but it creates no national register of security interests. Cybernetic Services endorsed that reading when it cited Trimarchi v. Together Dev. Corp., 255 B.R. 606, 610 (D. Mass. 2000), and the Sixth Circuit reached the same conclusion in In re Roman Cleanser Co., 802 F.2d 207 (6th Cir. 1986). Two qualifications belong here. Cybernetic Services itself noted academic disagreement and cited White and Summers against the Peregrine reasoning. Congress also amended §261 in 2012 to read “An interest that constitutes an assignment, grant or conveyance,” language the Ninth Circuit has not revisited, so careful counsel still records at the PTO even though the recording itself proves nothing. A San Diego company argues all of this from binding authority rather than persuasive authority, which is its own kind of advantage.

3. The Technology You Licensed In Was Never Yours to Pledge

A large share of San Diego companies did not invent the thing at the center of the business, they licensed it, and the counterparty is usually a university or institute technology transfer office or a pharmaceutical partner, with a grant that is nonexclusive or field-limited and a consent requirement buried in the assignment clause. Federal law treats that document very differently from a patent you own. In Everex Systems, Inc. v. Cadtrak Corp. (In re CFLC, Inc.), 89 F.3d 673 (9th Cir. 1996), the Ninth Circuit held that “federal law governs the assignability of nonexclusive patent licenses, and because federal law makes such licenses personal and assignable only with the consent of the licensor,” the license could not be assumed and assigned in bankruptcy under 11 U.S.C. §365(c).

State commercial law softens that only halfway, and the half it does not soften is the half that matters to a creditor. Cal. Com. Code §9408(a) makes a contractual term restricting assignment of a general intangible ineffective to the extent it would impair the creation, attachment, or perfection of a security interest, which is why a funder’s lien does technically attach to your in-license. Subdivision (d) then removes essentially everything a lien is for, starting with the rule that the interest “is not enforceable against the person obligated on the promissory note or the account debtor.” It “does not entitle the secured party to use or assign the debtor’s rights,” and it gives no right to “use, assign, possess, or have access to any trade secrets or confidential information” of the licensor. Subdivision (d)(6) finishes the job: it “does not entitle the secured party to enforce the security interest” in that general intangible at all.

Sit on the licensor’s side for a moment, because it explains behavior that otherwise looks obstructive. A technology transfer office that granted a field-limited license to a named startup priced its diligence obligations, milestones and sublicensing economics against that specific company and team, and it has no interest in waking up with a receivables funder or a distressed buyer standing in the licensee’s shoes. Its consent right is the only leverage it holds, it knows the license is often the entire business, and it will use consent to reopen terms that were settled years ago. Any restructuring that contemplates a sale has to budget for that conversation early rather than discovering it in diligence.

The practical consequence for a workout is blunt. If your core patents are in-licensed rather than owned, the funder’s blanket filing covers a contract right it cannot enforce, cannot assign, and cannot use, which is a meaningfully weaker position than the funder believes it holds when it opens the call. It is also a citable argument for a discount, and one of the few in this area that improves rather than degrades when the other side takes it to counsel, because counsel reads subdivision (d) and reaches the same place.

4. Federal Award Money Was Never Cash on Hand

Founders describe an SBIR award or a foundation grant as money in the bank, and creditors hear it the same way, but the uniform grant rules treat those funds as restricted from the moment they arrive. 2 C.F.R. §200.316 provides that property acquired or improved with a federal award “must be held in trust by the recipient or subrecipient as trustee for the beneficiaries of the project or program.” Section 200.313(a)(2) adds that while equipment is used for its authorized purpose the recipient “must not dispose of or encumber its title or other interests without the approval of the Federal agency or pass-through entity.” A blanket lien that sweeps in the sequencer bought with award funds is an encumbrance nobody approved.

Cash behaves the same way, which is why there is rarely a pile of grant money sitting there for a creditor to reach. Under 2 C.F.R. §200.305(b)(1) advance payments “must be limited to the minimum amounts needed and be timed with actual, immediate cash requirements,” as close as administratively feasible to actual disbursements. A compliant recipient therefore draws down against costs already incurred rather than banking the award. A funder debiting the operating account of a grant-funded company is frequently taking money drawn for a specific budget line, which creates an award compliance problem for you long before it creates a collection problem for them.

Whether a creditor can reach the payment stream itself depends on which instrument you actually hold, and the SBIR statute is explicit that there are three. 15 U.S.C. §638(e)(3) defines a funding agreement as “any contract, grant, or cooperative agreement entered into between any Federal agency and any small business” for experimental, developmental, or research work. If yours is a contract, 41 U.S.C. §6305(a) says the contractor “may not transfer the contract or order, or any interest in the contract or order,” and a purported transfer annuls the contract as far as the government is concerned. Section 6305(b) then permits assignment of amounts due only to a bank, trust company, federal lending agency or other financing institution. It must also cover the full balance, run to a single assignee, and carry written notice filed with the contracting officer, the surety and the disbursing officer.

Be careful with how far you push that, because the honest answer includes what is unresolved. The parallel restriction at 31 U.S.C. §3727 covers assignment of a claim against the United States, and it carries its own financing institution exception for contracts with payments totaling at least $1,000. Courts have long treated these protections as running to the government’s benefit rather than the contractor’s, and we could not locate a published decision squarely holding that a merchant cash advance company is or is not a financing institution within either statute, and we are not going to imply one exists. What is safe to say is narrower and still useful: almost no advance funder files the notices these sections require, and an unfiled assignment is not one the government has to honor.

5. What Bayh-Dole Keeps Inside the Patent You Are Selling

If any part of the invention was made with federal support, the patent you are pledging or selling carries permanent passengers, and a buyer’s counsel will find them in the first week of diligence. Under 35 U.S.C. §202(c)(4), where the contractor elects rights the funding agency “shall have a nonexclusive, nontransferrable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any subject invention throughout the world.” That license survives a sale, a foreclosure, and a bankruptcy. For a defense-adjacent technology whose realistic customer is the government, a paid-up federal license is not a footnote, it is a discount on the whole asset.

Two further provisions shape what a distressed transaction can look like, and the first is march-in. Section 203 lets the funding agency require the contractor, an assignee, or an exclusive licensee to grant a license to a responsible applicant on reasonable terms, and to grant one itself if that is refused. The triggers include a failure to take effective steps toward practical application and unmet health or safety needs. Section 204 then bars a small business firm or nonprofit, or any assignee, from granting an exclusive right to use or sell a subject invention here unless the licensee agrees that products will be manufactured substantially in the United States. That one is waivable, but only on a showing that reasonable efforts failed or that domestic manufacture is not commercially feasible.

Now the correction, because this one is repeated confidently in a great deal of startup advice and the statute says otherwise. The prohibition on assigning rights to a subject invention without agency approval lives at §202(c)(7)(A), and that paragraph opens with the words “In the case of a nonprofit organization,” so it does not apply to a small business firm on its face. Your specific funding agreement or agency supplement may still impose approval or reporting duties, and you should read it rather than the statute alone. But if someone tells you a venture-backed company categorically cannot assign a Bayh-Dole subject invention without written agency consent, ask them to point at the sentence.

The deadlines matter more than any of it in practice, because they are where title actually gets lost. Section 202(c)(1) requires disclosure of each subject invention within a reasonable time after it becomes known to the personnel responsible for patent matters, and it provides that the government may receive title to anything not disclosed in time. Section 202(c)(2) sets a two-year written election window, and §202(c)(3) requires a patent application before the §102(b) bar date. A company that let disclosures slide during a cash crisis can arrive at a sale with a cloud on the very asset it is selling, and that is a problem no settlement negotiation fixes.

6. An Advance Bought Against Receipts That Do Not Exist

A merchant cash advance is a purchase of a specified amount of future receipts at a discount, remitted daily or weekly, and the entire product is built on the assumption that receipts arrive continuously from many customers. A pre-revenue company has no such stream, so what the underwriter is really pricing is the pattern of deposits in three months of statements, which at a biotech means grant drawdowns, an investor wire, a milestone payment from a partner, and possibly a tax credit refund. None of that is a receipt from operations, and every dollar of it is either restricted, non-recurring, or contingent on somebody else’s decision.

Run the arithmetic on a file we would recognize immediately, where a company burning $250,000 a month takes $150,000 against a $217,500 payback at a 1.45 factor, remitted at roughly $1,812 per business day over 120 business days. The advance buys about eighteen days of runway, and the remittance takes about $38,000 a month back out, which is roughly fifteen percent of the entire monthly burn, for the next five to six months. The cost is $67,500 on $150,000 in under half a year, and the annualized figure that Financial Code §22802(b)(6) exists to force onto the disclosure page is the number nobody in the sales call said out loud.

What that pricing tells you about the transaction is more useful than the pricing itself, because a funder that underwrote a company with no operating revenue was not underwriting revenue at all. It was underwriting the personal guaranty, the deposit account, and the probability that the next equity tranche would arrive in time to service the debits. Brokers who place these deals are compensated on funded volume, which is why an early-stage company declined by every venture debt desk in the county can receive three term sheets in a week. Understanding that the deal was placed rather than underwritten is the first honest step in valuing it.

It also matters for how the paper gets characterized, because the defense to a merchant cash advance usually turns on whether the transaction was a true purchase of receivables or a disguised loan. The features courts look at are the reconciliation provision, the absence of a fixed maturity, and the funder’s assumption of performance risk, and those features are at their weakest where there were no receivables to purchase in the first place. It is a genuine argument, but it is a litigation argument rather than a settlement argument, and it belongs with counsel rather than in a phone negotiation.

7. The New Filing That Breached the Loan You Already Had

Venture debt is the quiet party in most of these files, and it is usually the party with the strongest legal position and the most to lose. Cal. Com. Code §9322(a)(1) ranks conflicting perfected security interests by priority in time of filing or perfection, dating from the earlier of when a filing covering the collateral was first made or the interest was first perfected. The venture lender that filed at closing therefore sits ahead of a funder who filed eighteen months later, regardless of who is being paid faster. Section 9339 then lets a secured party subordinate by agreement, which is why an intercreditor or subordination agreement, not the index, is the document that finally settles rank.

The damage a new advance does is usually contractual rather than a priority fight. The venture loan agreement carries negative covenants prohibiting additional indebtedness and additional liens, frequently a minimum cash or liquidity test, and a material adverse change clause. A new financing statement on the public index is discoverable within days by a lender running monthly searches. The lender does not have to prove damage. It has to point at the covenant, declare a default, and then decide what it wants, which is typically a forbearance priced in additional warrants, a tighter cash covenant, and a demand that the advance be paid off.

The deposit account is the part founders underestimate, because where the lender is also the bank holding your operating account, or where a signed control agreement is in place, control exists under Cal. Com. Code §9104(a)(1) or (a)(2). The lender can then apply the balance without a judgment and without notice to anyone, which is a materially different remedy from anything an advance funder holds. Companies in this position sometimes react by moving the operating account, and that reaction is worth pausing on. Changing where the money sits, or revoking a payment authorization, is a legal act with consequences under both agreements, and it should be taken on advice rather than in a bad week.

There is a sequencing lesson in all of this that costs nothing to apply, since a venture lender who learns about an advance from a covenant breach behaves very differently from one who was told beforehand. The first has a control problem and the second has a credit problem, and only one of those makes a lender feel it has to act immediately. Where a stacked position already exists, the venture lender is frequently the most useful party at the table. It holds a first-priority interest in the same collateral and no interest whatsoever in a junior funder converting its claim into a judgment.

8. The Tranche That Does Not Fund, and the Order That Reaches the Next One

Tranche financing is the structural fragility that makes these workouts different from every other kind. Money arrives in slices conditioned on data, a regulatory clearance, a first-in-human dosing, a successful flight test, or a prime contract award, and the investor holds a right to decline the next slice when the condition is not met. That is not a lender exercising a remedy after default. It is a counterparty electing not to buy, and there is nothing to negotiate with and nothing to restructure. The enterprise value of the company sits almost entirely in the expectation that the slice arrives. Value here can therefore go to near zero in a single board meeting while every asset on the balance sheet stays exactly where it was.

Any creditor conversation therefore runs against a clock the creditor cannot see and you can. A missed covenant that triggers an investor walk-away right, a stacked advance that shows up in an investor’s diligence refresh, or a judgment on the public docket can each independently end the financing, and once it ends the recovery for every creditor collapses at the same moment. That shared exposure is genuine leverage in a settlement discussion, because a funder that understands its collateral is worth materially less on the other side of a failed round has a reason to take a discount now rather than a theoretical number later.

California gives a judgment creditor a specific tool aimed at exactly the payments a milestone-funded company expects. Code of Civil Procedure §708.510(a) lets a court, on noticed motion, order the judgment debtor to assign to the creditor or to a receiver all or part of a right to payment due or to become due, “whether or not the right is conditioned on future developments.” The enumerated examples include royalties at (a)(4) and “payments due from a patent or copyright” at (a)(5). Section 708.520 lets the creditor obtain an order, ex parte where the court permits, restraining you from assigning or disposing of that right while the application is pending, and §708.620 permits appointment of a receiver where that is a reasonable method of obtaining fair and orderly satisfaction.

Read those three sections together and the risk profile of letting a case go to judgment becomes concrete rather than abstract. A creditor with a judgment does not need to sell your patents to hurt you; it can ask a court to route your future royalty and milestone payments to itself, and the statute expressly reaches rights that are still contingent. Very few advance funders litigate to that point, because the cost and delay rarely justify it against a small balance. The possibility is still the reason a pre-revenue company should resolve or defend a suit rather than ignore it.

9. On the Defense Side, Ownership Moves Are Filings

A restructuring that changes who owns a defense electronics or unmanned systems subcontractor is not a private transaction, and the deadlines are short enough to catch people who did the corporate work first and the compliance work second. Under 22 C.F.R. §122.4(a), a registrant must notify the Directorate of Defense Trade Controls in writing within five days of a change in its legal organization structure, its ownership or control, or its board, senior officers, partners or owners. Under §122.4(b), it must notify DDTC by registered mail “at least 60 days in advance of any intended sale or transfer to a foreign person of ownership or control of the registrant or any entity thereof.” Registration itself is a recurring cost, starting at a $3,000 tier one fee under §122.3(a)(1). That is a line item cash-strapped companies sometimes let lapse at exactly the wrong moment.

Foreign investment review sits on top of that, and the rule that governs distressed financing is unusually specific. 31 C.F.R. §800.306(a) provides that a loan or similar financing arrangement by a foreign person, even one secured by the company’s assets, does not by itself constitute a covered transaction. Section 800.306(a)(1) adds that the Committee will accept a filing on such an arrangement only when, because of imminent or actual default or other condition, there is a significant possibility the foreign person may obtain control or the rights described in §800.211(b). Subsection (b) is the trap. A financing “through which a foreign person acquires an interest in profits of a U.S. business, the right to appoint members of the board of directors, or other comparable financial or governance rights characteristic of an equity investment but not of a typical loan may constitute a covered transaction.”

That sentence describes a fair number of rescue instruments, since a convertible note with board observer rights, a revenue-share arrangement, a warrant package, or a restructuring in which a foreign strategic partner takes equity for forgiving debt can all land inside that definition. Where the company produces or develops critical technology requiring export authorization to that acquirer, 31 C.F.R. §800.401(c) can make a declaration mandatory rather than voluntary. The penalty for getting that wrong is not small. Section 800.901(b) provides a civil penalty not to exceed $5,000,000 or the value of the transaction, whichever is greater.

Sequence the compliance work into the deal rather than after it, because where a cleared facility is involved the notification obligations under the industrial security rules begin when negotiations start rather than when they close. An ITAR registrant that reports a change of ownership on day forty of a sixty-day clock has already created a problem no amount of good faith unwinds. The order that works is to identify the filings first, build the closing timetable backward from the longest one, and only then negotiate the economics. A transaction that cannot be filed on time is not a transaction.

What a Clearance Adjudicator Reads in a Workout File

Debt is a security issue in this industry in a way it is not anywhere else, and the rules say so in plain words. The adjudicative guidelines published at 32 C.F.R. §147.8 identify a history of not meeting financial obligations and an inability or unwillingness to satisfy debts among the conditions that may be disqualifying for access to classified information. Those same guidelines then list the mitigating conditions, and two of them describe a company owner in a workout almost exactly: that the conditions producing the behavior “were largely beyond the person’s control,” with a business downturn given as an express example, and that “the individual initiated a good-faith effort to repay overdue creditors or otherwise resolve debts.”

The entity-level rule points the same direction. 32 C.F.R. §117.11(a)(6) provides that changed conditions, “such as a change in ownership, indebtedness, or a foreign intelligence threat,” may justify adjustments to the security terms under which an entity operates, which is the regulation telling you outright that company debt is a reportable condition rather than a private commercial matter. When the agency lists the measures that can mitigate foreign ownership, control or influence that is not ownership-based, §117.11(d)(1)(iv) names “elimination or resolution of problem debt” alongside modification of foreign loan agreements and demonstration of financial viability independent of foreign interests.

Read in that light, a documented settlement program is not merely a cash management decision, it is evidence in the file, and the sequence matters more than the outcome. A negotiation that is papered, dated and performed produces exactly the record the mitigating conditions describe, while an unpaid balance sitting in collections for two years produces the disqualifying one. One honest caveat: these are the guidelines codified in the Code of Federal Regulations, and the executive branch has since issued the National Security Adjudicative Guidelines in Security Executive Agent Directive 4, which carries its own financial considerations guideline. Confirm which version your cognizant security agency applies before you rely on any specific wording.

The California Rules That Frame a San Diego Negotiation

Two features of California law change the tempo of these files and both cut in your favor. The first is that a creditor here has to litigate before it can touch anything, because Code of Civil Procedure §1132(a) makes a judgment by confession unenforceable and bars its entry in any superior court, with §1132(b) reaching back only to judgments obtained or entered before January 1, 2023. A funder whose form agreement was drafted for a state that still permits the device has to file a complaint, serve it, and win, and every week of that is a week your next tranche might land.

The second is that the state disclosure regime frequently does not reach the deals a life science company signs, which is a fact worth knowing precisely rather than assuming in either direction. Financial Code division 9.5 requires a signed disclosure before consummation, but §22800(n) defines the protected recipient as a person presented an offer of $500,000 or less, and §22801(a) removes depository institutions from the division entirely. A $3,000,000 venture facility from a bank sits outside the statute on both grounds at once, while the $150,000 advance that arrived through a broker sits squarely inside it, so the disclosure argument tends to exist against exactly one creditor in a stack of four.

Neither point should be oversold, and dating the statement matters as much as making it. Division 9.5 contains no express private right of action, so a disclosure failure is generally an argument that supports a negotiation and a regulatory complaint rather than a claim you file, and the analysis has to be run against the law as it stood on your funding date rather than as it stands today. Where a filing office is involved, the answer is always Sacramento under Cal. Com. Code §9501(a)(2), and a San Diego County search will simply return nothing on collateral that is not real property or fixtures.

Sequencing a Pre-Revenue File, and When Not to Hire Anyone

The order these files get worked is not the order the phone rings. The first pass is documentary and takes about a week: a current Secretary of State search read for collateral descriptions and filing dates, every funding agreement with its addenda, the venture loan with its covenant schedule, every in-license and sponsored research agreement pulled for its assignment and consent clauses, the award documents for any federal money with the instrument type identified, and a schedule of which patents are owned outright and which are licensed. Only after that does anyone have a defensible view of what there is to settle, and on roughly half the files that exercise moves the number materially.

The second pass is the counterparties who are not creditors but hold vetoes, which is the piece generic advice always misses. A licensor with a consent right, an investor holding a walk-away right on the next tranche, a prime contractor with a novation or flow-down interest, and a cognizant security agency all have the power to end a transaction that looks finished, and each of them behaves better when informed early than when surprised late. Only in the third pass do the advances get worked as a group, in priority order, with the weakest positions negotiated against the strongest arguments rather than one call at a time.

Delancey Street is a business debt settlement company working with a nationwide network of licensed attorneys, and it is not a law firm, which on this kind of file is an operational distinction rather than a disclaimer. Negotiating the advances, reconstructing what was actually funded against what was represented, pricing a payoff and obtaining lien terminations is settlement work. Suing over a characterization defense, responding to an assignment order application, papering a subordination agreement with a venture lender, or filing a chapter 11 is legal work handled by counsel within the network.

Of the three companies listed on this page, only the first works a commercial debt file end to end, from the opening funder call through recorded lien terminations, while the other two are built around broader consumer and household debt programs, so pick against what your file actually is. There are also files where paying anyone is a waste of scarce cash, and they look like one modest advance, a clean index, cash in the bank and a funder returning calls. Founders in that position should read the San Diego MCA overview and the broader California business debt settlement guide and handle it themselves.

Who Should You Call? Our Top-Rated Business Debt Firms

One firm on this list works the entire lifecycle of a business debt file, from stopping the daily debits through attorney-led negotiation, UCC lien removal, and a signed release. The other two cover broader debt categories that often sit alongside the advances. Choose accordingly.